Clinical article · Specialties, Medicines and results

Opioid conversion and anticipatory prescribing in the last days of life

Written for
Hospital physicians, emergency doctors and residents
Reading time
7 minutes
Published
Updated

Written by the Sana Health team for clinicians. It summarises published guidance, is not a guideline and has not been peer reviewed. Check current local protocols before acting.

Key points

  • Conversion ratios rest on limited evidence and differ between references, so the ratio and its source should be written down with every conversion.
  • Changing the route of the same opioid needs only the route ratio; changing to a different opioid also needs a dose reduction for incomplete cross-tolerance.
  • The breakthrough dose is usually one sixth to one tenth of the 24-hour dose and is recalculated whenever the regular dose changes.
  • In severe renal impairment, morphine and similar opioids accumulate, and an alternative or a reduced dose is chosen by local guidance.
  • Anticipatory prescriptions cover pain and breathlessness, agitation, nausea and respiratory secretions, each with dose, frequency and a 24-hour maximum.

Recognising the last days

Many people die in acute hospitals, where care in the last days is often less good than it could be; a structured care programme for the dying phase has been tested in a cluster randomised trial in older inpatients [8]. The practical signs that a patient may be entering the last days are profound weakness, spending most of the day in bed, a falling intake of food and fluid, increasing drowsiness and difficulty swallowing tablets. Recognition is uncertain, so the assessment should be shared, discussed with the patient where possible and with the family, and reviewed daily.

Once the oral route is failing, regular medicines need a new route, and the symptoms that commonly arise in the last days need prescriptions in place before they occur. Palliative care guidelines recommend opioids, anticholinergics, antipsychotics and benzodiazepines for these symptoms, although the evidence base is limited [7].

Opioid conversion: the principles

Conversion ratios come largely from studies with methodological flaws [2], and the evidence for switching opioids is itself limited [6]. Guidance from the European Association for Palliative Care [1] and, more recently, an international guideline on opioid conversion in adults with cancer [3] emphasise assessment before the change, consensus-based ratios and close monitoring afterwards [4].

  1. Add up the total opioid taken in the last 24 hours, including breakthrough doses that were genuinely needed.
  2. Choose a recognised conversion ratio for the new drug or route, and write down the ratio and its source.
  3. If the drug itself is changing, not only the route, reduce the calculated dose, commonly by 25% to 50%, for incomplete cross-tolerance.
  4. Set the breakthrough dose at about one sixth to one tenth of the new 24-hour dose.
  5. Review within 24 hours for pain control and toxicity, and adjust.

A worked example

A man with metastatic pancreatic cancer takes oral morphine 60 mg twice daily, can no longer swallow, and has an eGFR of 24 mL/min/1.73 m2.

StepCalculation
Total oral morphine in 24 hours60 mg twice daily = 120 mg
Route ratio, oral to subcutaneous morphine2:1 in many palliative care references, including UK guidance; some tables use 3:1
Subcutaneous morphine over 24 hours at 2:1120 / 2 = 60 mg by syringe driver
Breakthrough dose at one sixth60 / 6 = 10 mg subcutaneously as needed
Renal functioneGFR 24: morphine metabolites accumulate, so an alternative opioid or a reduced dose is considered

Because his renal function is poor, many guidelines would switch to an opioid less dependent on renal clearance rather than continue morphine. That is a change of drug, so the ratio for the new opioid would be taken from the local formulary and the result reduced for incomplete cross-tolerance. The figures above illustrate the method; they are not a prescription.

Ratios differ between references and countries. Check every conversion against the local palliative care guideline or formulary, and ask the palliative care team when doses are high or the change is complex.

Opioids in renal impairment

Opioids differ in how they behave when the kidneys fail [5]. Morphine, diamorphine and codeine have metabolites that accumulate, causing drowsiness, confusion, myoclonus and respiratory depression. In severe renal impairment, guidance generally favours fentanyl, alfentanil or buprenorphine at cautious doses, with others such as oxycodone used with care at reduced doses, and expert consensus guidance exists for symptom management in patients dying with advanced chronic kidney disease [1, 5, 9]. Whatever the drug, smaller doses and longer intervals are safer, and the patient is reviewed often.

Anticipatory prescribing

SymptomDrug classPractical points
Pain and breathlessnessOpioid, subcutaneous, as neededDose from the regular opioid, or a low starting dose if opioid-naive
Agitation and anxietyBenzodiazepine, such as midazolamLook first for pain, urinary retention, constipation and hypoxia; other routes are being studied [12]
Nausea and vomitingAntiemetic chosen by likely causeHaloperidol, levomepromazine, metoclopramide or cyclizine by mechanism
Respiratory secretionsAntimuscarinic, such as hyoscine butylbromide or glycopyrroniumWorks best early; reposition and explain the noise to the family

Each prescription should state the indication, dose, route, minimum interval and maximum in 24 hours. For respiratory secretions, the evidence for treating established death rattle is limited [11], but prophylactic subcutaneous scopolamine (hyoscine) butylbromide reduced its occurrence in a randomised trial [10].

Where injectable morphine or midazolam is difficult to obtain, as in some hospitals in India and elsewhere, the plan should be made early with the pharmacy, using alternatives and routes that local guidance allows.

Subcutaneous infusions and care in the last days

  • A syringe driver delivers the 24-hour dose of one or more drugs; check compatibility in a recognised reference before mixing, and use as few drugs as needed.
  • Inspect the site daily for inflammation, which reduces absorption.
  • Continue an existing fentanyl patch and add subcutaneous doses as needed; do not start a new patch in the last days, because it takes many hours to reach effect.
  • Stop medicines and routine observations that no longer help, and decide on hydration and nutrition for the individual patient.
  • Provide mouth care, support the family, and make resuscitation decisions according to local law and policy.

Traps

  • Switching to a different opioid without a dose reduction.
  • Continuing morphine at full dose as renal function falls.
  • Leaving the breakthrough dose unchanged after the regular dose has been increased.
  • Under-treating pain from fear of opioids in a patient who is dying.
  • Prescribing drugs that are not stocked on the ward at night.
  • Involving the palliative care team only after the patient has become distressed.

How Sana Health helps

Given the current analgesia with doses, renal and liver function, the symptoms and what the patient and family want, the Palliative and Supportive Care engine writes a Symptom Plan table and, when a drug or route changes, a Conversion Calculation showing the 24-hour total, the ratio and its source, the reduction for cross-tolerance, the new 24-hour dose and the breakthrough dose. When the patient may be in the last days it adds Anticipatory Prescriptions with dose and frequency, and states that conversions must be checked against the local formulary.

Questions

How much should the dose be reduced when switching opioids?

When changing from one opioid to another, the calculated equivalent dose is commonly reduced by 25% to 50% for incomplete cross-tolerance, with a larger reduction when doses are high or the patient is frail. A change of route with the same drug does not need this reduction.

What is the breakthrough dose of an opioid?

Usually one sixth to one tenth of the total 24-hour regular dose, given as needed, and recalculated whenever the regular dose changes. Frequent use of breakthrough doses is a signal to review the regular dose.

Which drugs go on an end-of-life anticipatory prescription?

Four drug classes are usually covered: an opioid (pain, breathlessness), a benzodiazepine (agitation), an antiemetic and an antimuscarinic (secretions), each written for subcutaneous use as needed with a dose, interval and 24-hour maximum, following the local guideline.

References

  1. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC (opens in a new tab)Lancet Oncol, 2012
  2. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review (opens in a new tab)Palliat Med, 2011
  3. Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline (opens in a new tab)Support Care Cancer, 2025
  4. Opioid Conversion in Adults With Cancer: MASCC-ASCO-AAHPM-HPNA-NICSO Guideline Clinical Insights (opens in a new tab)J Pain Symptom Manage, 2026
  5. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project (opens in a new tab)Palliat Med, 2011
  6. Opioid switching to improve pain relief and drug tolerability (opens in a new tab)Cochrane Database Syst Rev, 2004
  7. Safety and Effectiveness of Palliative Drug Treatment in the Last Days of Life-A Systematic Literature Review (opens in a new tab)J Pain Symptom Manage, 2018
  8. Improving comfort around dying in elderly people: a cluster randomised controlled trial (opens in a new tab)Lancet, 2017
  9. Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group (opens in a new tab)Palliat Med, 2009
  10. Effect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of Life: The SILENCE Randomized Clinical Trial (opens in a new tab)JAMA, 2021
  11. Interventions for noisy breathing in patients near to death (opens in a new tab)Cochrane Database Syst Rev, 2008
  12. A randomized controlled clinical trial of intranasal versus subcutaneous midazolam for agitation in terminal illness (MinTU study) (opens in a new tab)Palliat Med, 2026